In August 2020, the article 'Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases' ( describing the discovery of an ATP-competitive pyrazolopyrazinyl series of TYK2 inhibitors was published. Lead optimization of the set of compounds through structure-based design, led to the identification of the clinical candidate PF-06826647, which binds to the catalytically active JH1 kinase domain. Now this drug candidate is in clinical development (Ph.II) for the treatment of some autoimmune diseases. PF-06826647 contains cyclobutane dinitrile moiety in its backbone.

We have made a set of compounds, which contain such part – the perfect start for your research!